The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2020

Filed:

Mar. 06, 2019
Applicants:

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Biogen MA Inc., Cambridge, MA (US);

Inventors:

Richard S. Blumberg, Waltham, MA (US);

Timo Rath, Cambridge, MA (US);

Kristi Baker, Brookline, MA (US);

Adam Mezo, Carmel, IN (US);

Zachary Taylor, Crestview Hills, KY (US);

Kevin McDonnell, Lexington, MA (US);

Rosa Maria Silva Garcia Grenha, Arlington, MA (US);

Assignees:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US);

BIOGEN MA INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/10 (2006.01); C07K 14/735 (2006.01); C07K 14/765 (2006.01); A61K 47/54 (2017.01); C07K 7/08 (2006.01); C12N 15/10 (2006.01); G01N 33/50 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 47/54 (2017.08); C07K 7/08 (2013.01); C07K 14/001 (2013.01); C07K 14/70535 (2013.01); C07K 14/765 (2013.01); C12N 15/1037 (2013.01); G01N 33/5023 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01); C07K 2319/40 (2013.01);
Abstract

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.


Find Patent Forward Citations

Loading…